Oruka Therapeutics (NASDAQ:ORKA) Price Target Raised to $86.00 at Leerink Partners

Oruka Therapeutics (NASDAQ:ORKA) had its target price hoisted by Leerink Partners from $58.00 to $86.00 in a research report sent to investors on Monday morning,Benzinga reports. They currently have an outperform rating on the stock.

Several other brokerages have also issued reports on ORKA. BTIG Research reaffirmed a “buy” rating and set a $73.00 target price on shares of Oruka Therapeutics in a research report on Friday. Barclays upped their price target on Oruka Therapeutics from $48.00 to $50.00 and gave the company an “overweight” rating in a research report on Friday. Wedbush reissued an “outperform” rating and issued a $45.00 price target on shares of Oruka Therapeutics in a research note on Friday. Stifel Nicolaus raised their price objective on Oruka Therapeutics from $47.00 to $72.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Piper Sandler assumed coverage on Oruka Therapeutics in a research note on Thursday, December 18th. They issued an “overweight” rating and a $75.00 price objective on the stock. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Oruka Therapeutics has an average rating of “Moderate Buy” and an average price target of $59.60.

Oruka Therapeutics Stock Performance

Shares of NASDAQ ORKA opened at $41.75 on Monday. Oruka Therapeutics has a 52-week low of $5.49 and a 52-week high of $42.41. The firm has a 50 day moving average price of $33.22 and a two-hundred day moving average price of $27.86. The stock has a market cap of $2.07 billion, a P/E ratio of -22.45 and a beta of -0.38.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings results on Thursday, March 12th. The company reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.16. Analysts predict that Oruka Therapeutics will post -3.41 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $32.37, for a total transaction of $226,590.00. Following the completion of the transaction, the insider owned 34,018 shares of the company’s stock, valued at $1,101,162.66. This trade represents a 17.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 21,000 shares of company stock worth $663,530 over the last ninety days. 24.69% of the stock is owned by company insiders.

Institutional Trading of Oruka Therapeutics

A number of institutional investors have recently bought and sold shares of ORKA. Royal Bank of Canada grew its holdings in Oruka Therapeutics by 47.2% during the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after acquiring an additional 365 shares during the period. Kennedy Capital Management LLC lifted its stake in shares of Oruka Therapeutics by 0.9% in the 4th quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company’s stock valued at $1,476,000 after purchasing an additional 420 shares during the period. Russell Investments Group Ltd. lifted its stake in shares of Oruka Therapeutics by 35.0% in the 4th quarter. Russell Investments Group Ltd. now owns 3,041 shares of the company’s stock valued at $92,000 after purchasing an additional 788 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Oruka Therapeutics by 62.4% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,352 shares of the company’s stock valued at $71,000 after purchasing an additional 904 shares in the last quarter. Finally, Los Angeles Capital Management LLC bought a new stake in shares of Oruka Therapeutics during the 4th quarter valued at about $37,000. Institutional investors own 56.44% of the company’s stock.

Key Headlines Impacting Oruka Therapeutics

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Leerink Partners raised its price target from $58 to $86 and kept an “outperform” rating — the new target implies roughly 106% upside from the recent share level, a headline catalyst for buying interest. Leerink Raises PT to $86
• Positive Sentiment: BTIG Research reiterated a “Buy” rating on ORKA, supporting the bullish analyst consensus. BTIG Buy Rating Reiterated
• Positive Sentiment: Price target raised to $50 (American Banking News report), adding another explicit valuation bump from the Street. Price Target Raised to $50
• Positive Sentiment: Wedbush reiterated an “Outperform” rating, reinforcing institutional support. Wedbush Outperform Reiterated
• Positive Sentiment: Guggenheim reaffirmed a “Buy” rating, adding to the cluster of buy-side endorsements. Guggenheim Buy Reiterated
• Positive Sentiment: Wall Street Zen upgraded ORKA, another vote of confidence that likely supports momentum in the shares. Wall Street Zen Upgrade
• Positive Sentiment: Oruka recently set a new 1-year high after reporting stronger-than-expected quarterly results (EPS beat), which appears to have sparked the analyst re-ratings and increased trading activity. New 1-Year High on Strong Earnings
• Neutral Sentiment: General company news was compiled in market news roundups today (MSN aggregator); useful for context but not a direct catalyst. Company News for Mar 16, 2026

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.